Australia seems poised to experience potentially transformative medication for obesity: Retatrutide. This dual agonist – targeting on both GLP-1 and GIP receptors – shows significant results in clinical research, indicating substantial decreases in weight. While availability is pending with TGA, a number of individuals battling obesity could ho